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Structural analysis of nuclear receptor subfamily V orphan nuclear receptors suggests that ligand-indepen-
dent mechanisms must regulate this subclass of receptors. Here, we report that steroidogenic factor 1 (SF-1)
and liver receptor homolog 1 are repressed via posttranslational SUMO modification at conserved lysines
within the hinge domain. Indeed, mutating these lysines or adding the SUMO isopeptidase SENP1 dramati-
cally increased both native and Gal4-chimera receptor activities. The mechanism by which SUMO conjugation
attenuates SF-1 activity was found to be largely histone deacetylase independent and was unaffected by the AF2
corepressor Dax1. Instead, our data suggest that SUMO-mediated repression involves direct interaction of the
DEAD-box protein DP103 with sumoylated SF-1. Of potential E3-SUMO ligase candidates, PIASy and PIASx
strongly promoted SF-1 sumoylation, and addition of DP103 enhanced both PIAS-dependent receptor sumoy-
lation and SF-1 relocalization to discrete nuclear bodies. Taken together, we propose that DEAD-box RNA
helicases are directly coupled to transcriptional repression by protein sumoylation.
Steroidogenic factor 1 (SF-1) and liver receptor homolog 1
(LRH-1) are two closely related transcription factors belong-
ing to the nuclear receptor subfamily V (NR5A) that contain a
highly conserved DNA binding domain (DBD), a large hinge
domain and a ligand binding domain (LBD) (Fig. 1A). Dro-
sophila melanogaster Ftz-F1 is the founding member of this
subfamily and interacts directly with the pair-rule gene product
of Ftz to control parasegmentation at early embryonic stages
(25). The mammalian orthologs SF-1 and LRH-1 are also
critical in tissue development and organogenesis (19, 27, 33).
During development, SF-1 is essential for male differentiation,
adrenogonadal morphogenesis, and terminal differentiation of
the ventromedial hypothalamus, and in the adult, this receptor
regulates genes involved in steroid biosynthesis and endocrine
signaling (34, 44). Although SF-1 null mice die at birth from
adrenal failure, SF-1 heterozygous mice live. However, further
analyses of these heterozygous mice show that despite seem-
ingly adequate levels of SF-1, the amount of active SF-1 pro-
tein is insufficient to overcome defects in adrenal morphogen-
esis (2, 3). In humans, SF-1 haploinsufficiency is associated
with severe adrenal disease and gonadal dysgenesis (1, 28).
LRH-1 acts far earlier in development than SF-1, as evidenced
by the embryonic lethality observed in LRH-1 null embryos
(33). In vitro and in vivo analyses have implicated LRH-1 in
bile acid homeostasis (13, 26), where a heterozygous pheno-
type has also emerged in the intestine (4). In addition, LRH-1
controls tissue conversion of androgens to estrogen by regu-
lating aromatase gene expression (7, 17)
Despite the fact that the high-resolution crystal structure of
LRH-1 revealed a large hydrophobic pocket within the LBD
(38), natural ligands have yet to emerge for this subclass of
receptors. As such, the question of how subfamily V receptors
are regulated is unclear. In many cellular contexts, this subclass
of receptors is active and presumably recruits coactivators in a
ligand-independent manner. NR5A receptor activity depends
on two distinct regions in the LBD, an activation function in
helix 1 and the C-terminal AF2 domain (8, 20). In both SF-1
and LRH-1, a repression domain has been identified in the
hinge region (32, 47). For SF-1, this domain is reported to
interact with the DEAD-box RNA helicase DP103 (Ddx20 or
Gemin-3) (49), although the precise mechanism of SF-1 re-
pression by DP103 is unknown.
Phosphorylation and sumoylation are posttranslational
modifications known to modulate nuclear receptors. Phos-
phorylation of SF-1 is proposed to increase receptor activity
by stabilization of the LBD and enhanced cofactor recruit-
ment (8, 11, 15). On the other hand, sumoylation of tran-
scription factors, such as Elk-1, Lef1, and nearly all steroid
nuclear receptors, results in their transcriptional repression
(5, 18, 35, 39, 42, 50). Sumoylation occurs at canonical
motifs of KXE, where  is a hydrophobic amino acid and
K is the acceptor lysine for covalent attachment of the small
ubiquitin-like modifier (SUMO). SF-1, LRH-1, and other
invertebrate NR5 receptors are predicted to be sumoylated
given the presence of a conserved IKSE or I/VKQE site in
the hinge region (Fig. 1A). SUMO modification of proteins
is analogous to ubiquitination, involving a three-step ATP-
dependent reaction. Processed SUMO protein is loaded
onto the heterodimeric E1 enzyme (SAE1/SAE2) and trans-
ferred from E1 to the sole E2 enzyme Ubc9, which then
mediates SUMO conjugation to the protein substrate with
aid from E3-SUMO ligases. Protein inhibitor of activated
stats (PIAS) proteins comprise the largest of three identified
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E3-SUMO ligase classes (29). This protein conjugation is
dynamic and easily reversed by Sentrin/SUMO-specific pro-
teases (SENP/SUSP), which cleave SUMO from its sub-
strate. However unlike ubiquitin conjugation, which primar-
ily facilitates protein degradation, SUMO modification of
transcription factors often results in transcriptional repres-
sion. Others have proposed that this repression involves
direct recruitment of histone deacetylases (HDACs) (40, 51)
or a relocalization of the SUMO-marked protein to promy-
elocytic leukemia protein (PML) nuclear bodies (9, 39).
Here we identify sumoylation as an important posttransla-
tional regulatory mechanism for dampening the activity of sub-
family V nuclear receptors. Potential mechanisms for sumoy-
lation-mediated repression were investigated and found to
involve a functional interaction between the receptor and the
DEAD-box RNA helicase DP103.
FIG. 1. Subfamily V receptors are sumoylated in the hinge region. (A) A schematic of the domain structures and percentages of protein identity
for Drosophila (dm) Ftz-F1 and mouse SF-1 and LRH-1 are shown, with SUMO sites (S) and phosphorylation sites (P) indicated. The repression
domain is also shown (R, black square). (B) An anti-HA Western blot of COS-7 lysates is shown after transfection with HA-epitope tagged SF-1
or LRH-1 and SUMO1 or GFP-SUMO1. The slower-migrating forms of each receptor are indicated (arrowheads), and all lysates were prepared
in the presence of NEM, an inhibitor of SUMO isopeptidases. (C) Western blots are shown for Y1 whole-cell lysates treated with () or without
() 20 mM NEM. Protein was detected with an anti-SF-1 antibody. Upshifted SF-1 after NEM treatment is indicated by an arrowhead. (D) An
anti-HA Western blot of COS-7 cells is shown for empty vector control (pCI), the HA–SF-1 wild type, and lysine mutants with sumoylated SF-1
(arrowhead) and nonsumoylated SF-1 (SF-1) indicated; SUMO1 was coexpressed in all conditions. A control immunoblot for SUMO1 is shown
below. (E) An anti-SUMO1 Western blot of HA-immunoprecipitated lysates from COS-7 cells transfected with the wild type or lysine mutants of
SF-1 is shown, with sumoylated SF-1 (arrowhead) and nonspecific bands (NS) indicated. A control immunoblot for HA–SF-1 expression is shown
below. One microgram of each plasmid was added for all transfections. (F) In vitro sumoylation of the in vitro-transcribed and -translated
35S-labeled wild-type and lysine mutants of SF-1 (1 l) was carried out as described in Materials and Methods. Unmodified SF-1 (SF-1) and
sumoylated SF-1 (arrowheads) are indicated. , anti; IP, immunoprecipitation; WB, Western blotting.
1880 LEE ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Plasmids. Full-length mSUMO1 (101 amino acids [aa]) was PCR amplified
from embryonic mouse hypothalamic-enriched cDNA with primers 5-CTCGA
GATGTCTGACCAGGAGGCAAAA-3 and 5-TCTAGACTAAACCGTCGA
GTGACCCCC-3, TA-cloned into pCRII (Invitrogen), and subcloned into
XhoI-XbaI pCI-neo. Processed His6-human SUMO1 (hSUMO1) (97 aa) was
subcloned from His6-hSUMO1-pcDNA3 (F. Poulat) into pGEX4T1 at BamHI.
Hemagglutinin (HA)-tagged murine SENP1 (mSENP1) was PCR cloned from
mouse hypothalamic-enriched cDNA with primers 5-CCGGAATTCATGTAC
CCATACGACGTACCAGATTACGCTAGCTTGGATGACACAGCTGATG
GGGTG-3 and 5-ACCTCTAGAGTCGACTCACAAGAGCTTCCGGTGGA
G-3 into EcoRI-SalI of pCI-neo. HA-tagged mSF1 in pCI-neo, HA-tagged SF-1
S203A, and green fluorescent protein (GFP)–HA–SF-1 in pCMV were described
previously (8). K119R, K194R, and 2KR mutants of HA–SF-1–pCI-neo and
GFP–HA–SF-1 were created by PCR mutagenesis (Stratagene). All Gal4 con-
structs contained a HA epitope tag N-terminal to the Gal4 DBD. A C-terminal
fragment containing the hinge-LBD (aa 105 to 462) of SF-1 and mutants was
generated by PCR from HA–SF-1–pCI-neo with primers 5-ACGCGTCCTTG
AAGCAGCAGAAGAAAGCA-3 and 5-AAGCTTTCAAGTCTGCTTGGCC
TG-3 and subcloned 3 to the HA-Gal4-DBD. A similar strategy was used to
create all pGAL-LRH-1 constructs with the LRH-1 (aa 198 to 562) fused to
Gal4. FLAG-mPIASx was cloned from RIKEN clone 4921511I02 with primers
5-CCGGAATTCATGGACTACAAAGACGACGACGACAAAGCGGATTT
CGAGGAGTTG-3 and 5-CCGCTCGAGTCACTGTTGCACAGTATCAG
A-3, and FLAG-mPIAS1 was cloned from mouse hypothalamic cDNA with
primers 5-CTCGAGATGGACTACAAAGACGACGACGACAAAGCGGAC
AGTGCGGAACTAAAG-3 and 5-CCGCTCGAGTCAGTCCAATGAGATA
ATGTC-3. PCR products were subcloned into pCI-neo, pBH4, and pGADT7.
pVP16-PIAS1 and pVP16-PIASx were generated by inserting FLAG-mPIAS1
and FLAG-mPIASx PCR fragments downstream of the VP16 activation do-
main in a pVP16 vector (Clontech). The following constructs were generous gifts:
T7 tagged-mPIASy pCMV (from R. Grosschedl), FLAG-mPIAS3 pCMV (from
K. Shuai), full-length mDP103 pcDNA3 (from Y. Sadovsky), and C-terminal
hDP103 pGEX (aa 414 to 824) and full-length 2FLAG-hDP103 pcDNA3 (from
C. Glass).
Cell transfections, luciferase assays, and metabolic labeling. COS-7 cells were
plated at a density of 50,000 cells/ml/12-well plate or 1.5  106 cells/10-cm-
diameter plate in medium (Dulbecco’s modified Eagle’s H21 with 4.5 g of
glucose/liter with 10% calf serum and antibiotics) 18 h prior to transfection.
Transfections were carried out by using FuGene 6 (Roche). For luciferase assays,
cells were transfected with no more than 500 ng of total DNA per well and
harvested 48 h after transfection (BD Pharmingen). All transfections were per-
formed in triplicate and repeated at least twice. Results were normalized to
-galactosidase activity and expressed as relative luciferase units or activation, as
indicated. For metabolic labeling, COS-7 cells were plated in full medium and
transfected 18 h after plating. Cys/Met-deficient medium (Dulbecco’s modified
Eagle’s H21 with 4.5 g of glucose/liter, 10% dialyzed fetal bovine serum, 2 mM
glutamine, and antibiotics) was added to washed cells 48 h posttransfection,
followed by 1 h of pulse-labeling with 350 Ci of [35S]Cys and [35S]Met (Redi-
vue, AGQ0080; Amersham), washing, and incubation in full medium for relevant
chase periods. Cells lysates were subjected to immunoprecipitation, sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and autora-
diography, and the signal was quantified by phosphorimaging.
Yeast interaction system. An expression cassette containing full-length mouse
SF-1 (no heterologous activation domain) was integrated in yeast strain YM4271
containing two integrated reporters, HIS and LacZ, driven by four tandem copies
of the SF-1 response elements, using the manufacturer’s protocols (Clontech).
Full-length FLAG-tagged mPIAS1, mPIASx, and mPIASy were subcloned into
pGADT7 for transformation into yeast reporter strains. Transformants were
plated on selective medium and analyzed on 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal) medium and by liquid -galactosidase assays.
Western analysis, immunoprecipitation, and coimmunoprecipitation. Cells
were washed twice in cold phosphate-buffered saline (calcium and magnesium
free); lysed in 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1 mM EDTA, 0.1%
NP-40, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, and pro-
tease inhibitors (Roche); and precleared by centrifugation at 14,000 rpm with a
Sorvall Microfuge for 30 min. When appropriate, all solutions contained 20 mM
N-ethylmaleimide (NEM; Sigma) to inhibit SUMO isopeptidases. Protein con-
centrations were determined by the Bradford method (Pierce). Equal amounts of
total protein were loaded for Western blot analysis. Wild-type and mutant
receptors were affinity purified by using anti-HA affinity matrix (Covance/Babco)
in lysis buffer (as described above), washed in a modified lysis buffer containing
300 mM KCl and 0.05% NP-40, and subjected to SDS-PAGE and Western
blotting following incubation with primary antibodies (anti-HA, 1:2,000 [Co-
vance/Babco]; anti-FLAGM2, 1:2,000 [Sigma]; anti-SUMO1, 1:500 [Zymed])
and a horseradish peroxidase-conjugated goat anti-mouse secondary antibody
(1:10,000; Bio-Rad). The signal was developed by chemiluminescence (ECL kit;
Amersham). For coimmunoprecipitation of FLAG-hDP103 and sumoylated
SF1, cells were transfected and lysed as for in vivo sumoylation in 10 mM NEM.
Lysates were incubated with anti-FLAG M2 agarose beads (Sigma) in pull-down
buffer (50 mM Tris HCl [pH 7.6], 150 mM NaCl, 0.5 mM EDTA, 0.01% NP-40,
2 mM NEM, protease inhibitors), and precipitates analyzed by Western blotting
(anti-HA, 1:2,000 [Covance/Babco]; anti-hDP103, 1:2,000 [BD Biosciences]).
Recombinant protein expression, in vitro sumoylation assay, and GST pull
downs. Recombinant His6-hSUMO1 (aa 1 to 97) was expressed and purified by
TALON chromatography (Clontech). Recombinant His6-hE1 (SAE1/SAE2) and
His6-hUbc9 were obtained commercially (LAE Biotech). In vitro-transcribed
and -translated 35S-SF-1 and variants thereof were produced (Promega) and
incubated with 150 ng of E1, 750 ng of His6-Ubc9, and 900 ng of His6-SUMO1
in 50 mM Tris (pH 7.6), 5 mM MgCl2, 1 mM dithiothreitol, and 2.5 mM ATP at
37°C for 1.5 h, and the reaction was stopped by boiling in protein loading buffer.
Samples were subjected to SDS-PAGE followed by autoradiography. Glutathi-
one S-transferase (GST) pull-down assays were carried out with 35S-SF-1 or
variants thereof and purified GST–C-terminal hDP103 as described previously
(15, 21).
Chromatin immunoprecipitation assay. HeLa luciferase reporter (Stratagene)
cells containing an integrated promoter-reporter of five Gal4 binding sites fused
to the luciferase gene were electroporated with pCI-Neo and HA-tagged pGal-
SF-1 constructs (4 g). The method used follows that described in reference 46,
with PCR conditions of 25 cycles at 95°C for 30 s, 53°C for 1 min, and 72°C for
1 min and by using primers described previously (40) to amplify a 5 330-bp
region of luciferase cDNA.
Nuclear localization and immunohistochemistry. COS-7 cells were plated at
6,000 cells/well in four-well chamber slides (Lab-Tek) and transfected in dupli-
cate 24 h later (total DNA, 0.5 g/well). At 48 h posttransfection, cells were fixed
in 4% paraformaldehyde, permeabilized in phosphate-buffered saline containing
0.3% Triton X-100, incubated with primary antibodies (rabbit anti-T7, 1:300
[ICL]; mouse anti-FLAGM2, 1:5,000 [Sigma]; mouse anti-SF2/ASF, 1:1,000
[Zymed]; goat anti-Sp100, 1:50 [Zymed]; mouse anti-PML [PG-M3], 1:75 [Santa
Cruz]) followed by secondary antibodies (Cy-3 goat anti-rabbit, 1:1,000; Cy3-
donkey anti-mouse 1:1,000 [Molecular Probes]; Texas Red rabbit anti-goat, 1:500
[Vector]), and imaged on a Zeiss LSM510 confocal microscope.
RESULTS
Subfamily V receptors are sumoylated in the hinge region.
Although sumoylation is known to repress steroid receptor
activity, this modification has not been investigated for so-
called orphan nuclear receptors, which can function in a li-
gand-independent manner. In a modified one-hybrid yeast
screen for SF-1 protein partners, we identified Ubc9 or the E2
SUMO conjugating enzyme as a strong interacting protein
(data not shown). We next sought to determine whether SF-1
and LRH-1 could be sumoylated. Indeed, sequence analysis of
all vertebrate species of SF-1 and LRH-1 revealed two highly
conserved canonical sumoylation motifs at the N- and C-ter-
minal hinge regions, while insect Ftz-F1 variants contained one
site in the N-terminal hinge region (Fig. 1A).
Sumoylation of both SF-1 and LRH-1 was demonstrated in
a cellular system, as evidenced by slower-migrating bands after
coexpression of receptor with either SUMO1 or GFP-SUMO1
(Fig. 1B). In addition, a similar slower-migrating SF-1 species
was detected in NEM-treated lysates made from both Y1 and
T3 cells (Fig. 1C and data not shown), suggesting that endog-
enous SF-1 is sumoylated. Further analysis revealed that
Lys194 served as the major acceptor lysine for SF-1 sumoyla-
tion, as evidenced by the loss of the slower-migrating band with
the single mutation K194R and double mutation (K119R and
K194R, referred to as 2KR) but not with K119R (Fig. 1D). Our
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results for SF-1 are similar to those of other recent reports (6,
22). The identity of these slower-migrating SF-1 species as
sumoylated receptors was confirmed by immunoprecipitation
of HA epitope-tagged SF-1, followed by Western blotting with
an anti-SUMO1 antibody (Fig. 1E), and as predicted, no
sumoylated species were observed with K194R or 2KR mutant
proteins. These results were confirmed in an in vitro sumoyla-
tion assay, with Lys194 identified as a major site and Lys119
presumed to be a minor sumoylation site (Fig. 1F). Amounts of
sumoylated SF-1 diminish in both the K194R and 2KR mu-
tants; the faint residual upshifted band observed in the 2KR
variant imply that a minor third site can be sumoylated in vitro.
Taken together, we conclude that subfamily V receptors are
sumoylated in vivo and in vitro.
Sumoylation of SF-1 attenuates transcriptional activity.
Previous studies identified a regulatory domain which when
mutated led to increased receptor activity; this domain con-
tained the major sumoylation site for SF-1 and LRH-1 (Fig.
1A) (32, 47). Consistent with these reports, we found increased
activity of NR5A promoter reporters with either SF-1 or
LRH-1 sumoylation mutants (Fig. 2A). Increased receptor ac-
tivity observed with both the K194R and 2KR receptor mu-
tants was not due to increased protein stability, as judged by
results from pulse-chase metabolic labeling experiments (Fig.
2B). Gal4–SF-1/LRH-1 fusion receptors containing the full
hinge and LBD also showed a dramatic increase in activity
following mutation of the sumoylation acceptor sites. Strik-
ingly, the single mutant K194R was at least 70-fold more active
than the wild type, and mutation of both sumoylation sites
(2KR) resulted in greater than 300-fold activation (Fig. 2C, left
panel). While K119R exhibited comparable activation to that
of the wild type, the double mutant at both Lys119 and Lys194
showed remarkable synergism; this is consistent with Lys119 as
a minor site. Similar to native receptors, Gal4–SF-1 and Gal4-
K119R are efficiently sumoylated, whereas Gal4-K194R and
Gal4-2KR exhibit no detectable sumoylation (Fig. 2C, left
lower panel). Nearly identical results were observed for Gal4–
LRH-1 constructs, where double mutation of K213R and
K289R in the hinge region led to strong receptor activation
(Fig. 2C, right panel).
To confirm that receptor sumoylation served to repress SF-1
activity, we asked whether removing the SUMO conjugate
from SF-1 with the SUMO isopeptidase SENP1 would yield
similar results, as observed with the SF-1 lysine mutants. In-
deed, coexpression of SENP1 with SF-1 and SUMO1 resulted
in a marked attenuation of sumoylated SF-1 (Fig. 3A). Fur-
thermore, activities of both the wild type and the K119R mu-
tant were enhanced after the addition of small amounts of
SENP1 expression vector (25 ng), reaching levels observed
with the K194R mutant (Fig. 3B, left panel). Addition of
SENP1 failed to activate the 2KR variant, providing further
evidence that Lys119 and Lys194 are the sites of sumoylation
(Fig. 3B, right panel). Collectively, our data suggest that
Lys194 plays a dominant role in mediating repression of SF-1
via sumoylation and that receptor sumoylation represents a
major silencing mechanism.
A DEAD-box protein mediates repression via SF-1 sumoy-
lation. The mechanisms by which protein sumoylation leads to
transcriptional repression are diverse. Recent literature sug-
gests that repression by sumoylation involves (i) nuclear relo-
calization with a concomitant decrease of promoter occupancy
or (ii) direct recruitment of HDACs. Therefore, we asked
whether sumoylation mutants differ in their subnuclear local-
ization. Both GFP-wild type and GFP-SUMO mutants yielded
nearly identical patterns of nuclear localization (Fig. 4A). Con-
sistent with these results, no apparent differences were noted
in the promoter occupancy of Gal4-wild type compared to the
K194R mutant as judged by chromatin immunoprecipitation
(ChIP) results with a HeLa cell line containing a stably inte-
grated Gal4 reporter (Fig. 4B). We next asked whether SF-1
sumoylation promotes recruitment of HDACs by using the
class I and II HDAC inhibitors, trichostatin A (TSA) and
sodium butyrate (NaBT). If HDAC recruitment is essential for
SUMO-mediated repression, mutating the major sumoylation
sites within SF-1 should prevent derepression by TSA or
NaBT. Instead, addition of TSA or NaBT led to a dramatic
increase in the activity of all receptor variants (Fig. 4C and D).
Our results differ from those recently shown for Elk-1, where
loss of sumoylation eliminates TSA sensitivity (51), and thus,
we suggest that repression of SF-1 via sumoylation is largely
HDAC independent.
For subfamily V, two types of repressors have been identi-
fied. The first includes the orphan nuclear receptors Dax1 and
SHP, which interfere with the AF2 in the LBD. The second is
the RNA helicase DEAD-box protein DP103 (32). Indeed,
while Dax1 was able to repress the Gal4-K194R mutant as
effectively as Gal4-wild type (Fig. 5A, left panel), DP103 was
ineffective at repressing the Gal4-K194R and 2KR mutants
(Fig. 5A, right panel, and data not shown). Moreover, addition
of SENP1 failed to abolish Dax1-mediated repression of SF-1
(Fig. 5B, left panel). In contrast, addition of SENP1 completely
eliminated DP103-mediated repression of Gal4–SF-1 (Fig. 5B,
right panel). Our work contrasts a recent report showing no
difference between DP103-mediated repression in wild-type
and K194R (22). This discrepancy may reflect a difference in
cell types or the significantly greater amounts of DP103 used
compared to experiments shown here. Nonetheless, our data
agree with those reported by Ou and colleagues showing
Lys194 to be essential for DP103 repression of SF-1 (32).
To test the hypothesis that sumoylation at Lys194 allows
DP103 to function as a repressor, interaction between DP103
and sumoylated SF-1 was explored by direct binding assays. As
shown previously, only the C-terminal half of DP103 interacts
with SF-1 (32). Mutation of Lys194 and/or Lys119 did not
result in an appreciable loss of binding, suggesting that Lys194
is not the sole determinant for DP103 interaction with SF-1
(Fig. 5C). Furthermore, DP103 is able to interact efficiently
with in vitro sumoylated forms of SF-1 (Fig. 5D). These results
provide evidence that the DEAD-box protein DP103 interacts
with sumoylated SF-1 and directly participates in receptor re-
pression.
DP103 promotes PIAS-dependent sumoylation and sub-
nuclear relocalization of SF-1. To further explore how DP103
may affect SF-1 activity, we first defined the optimal E3-SUMO
ligase in vivo. One of the defining characteristics of an E3-
SUMO ligase is its ability to interact with and promote sumoy-
lation of a given substrate. In both the yeast and mammalian
two-hybrid assays, SF-1 interacted strongly with PIAS1 and less
well with PIASx and PIASy (Fig. 6A and B). However, de-
spite this strong interaction, PIAS1 does not serve as an effi-
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cient E3-SUMO ligase for SF-1 in vivo. In a survey of four
PIAS members, only PIASx and PIASy promoted SF-1
sumoylation in a dose-dependent manner; this effect was not
observed for PIAS1 or PIAS3 (Fig. 6C, left panel). In contrast
to results from the in vitro assay, overexpression of PIAS
proteins in vivo does not reveal detectable sumoylation at
noncanonical sites, as evidenced by the 2KR mutant (Fig. 6C,
right panel, and data not shown). Interestingly, mutating the
major phosphorylation site of SF-1 adjacent to Lys194 (S203A)
had no effect on receptor sumoylation (Fig. 6C, right panel).
Next, the functional effects of overexpressing PIAS proteins on
wild-type and 2KR receptors were determined. Consistent with
FIG. 2. Sumoylation represses SF-1 transcriptional activity. (A) Transcriptional activity of the wild type and lysine mutants of SF-1 (50 ng) on
the aromatase-luciferase reporter (Aro-Luc, 500 ng) is shown for both COS-7 (no SUMO1 added) and HepG2 cells (50 ng of SUMO1 added).
Other promoter-luciferase reporters used in HepG2 cells were the 3-hydroxysteroid dehydrogenase promoter (3HSD Luc, 153/2 bp), a
synthetic promoter containing tandem SF-1 response elements from the mouse Mu¨llerian inhibiting substance promoter (2XRE MIS), and the
StAR promoter (StAR Luc, 966/1); 250 ng of each promoter was used. (B) The stability of wild-type (WT) and lysine mutant (K194R or 2KR)
SF-1 proteins in COS-7 cells was determined after metabolic labeling, followed by a chase for 0, 2, 5, and 12 h. An autoradiogram of
immunoprecipitated HA proteins from whole-cell lysates is shown, with phosphorimaging data graphed as the percentage of labeled protein
remaining after each chase period; levels of protein at time zero were taken to be 100%. (C) Transcriptional activity is shown for the Gal4–SF-1
wild type (pGalWT, aa 105 to 462, 25 ng) or Gal4–SF-1 lysine mutants (pGalK119R, pGalK194R, and pGal2KR; 25 ng) on the Gal4-luciferase
reporter (pFR-Luc, 200 ng; Stratagene) in COS-7 cells (left panel). Anti-HA Western blotting shows expression levels of the Gal4–SF-1 WT or
KR mutants, with slower-migrating forms of sumoylated Gal4–SF-1 protein indicated (arrowhead). Transcriptional activities of the Gal4–LRH-1
wild type (pGalWT, aa 198 to 560, 25 ng) and lysine mutants (pGalK213R, pGalK289R, and pGal2KR) are shown (right panel). All luciferase
activity is expressed as activation over parent vectors: pCI-neo (C) for panels in A and pM (pGal) for panels in C. Hrs, hours; WB, Western
blotting.
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PIAS-dependent activation of other nuclear receptors (24), we
observed an initial activation phase, followed by repression
when PIASx is added to the wild-type receptor (Fig. 6D).
Addition of SUMO1 further enhanced receptor repression,
suggesting that increased sumoylation does silence SF-1 activ-
ity. In contrast, increased repression was not observed with the
double mutant 2KR (Fig. 6E). The global repression observed
with increasing amounts of SUMO1 added to either wild-type
or mutant receptors most likely reflects the multiple nuclear
substrates affected by the sumoylation machinery, including
corepressors and coactivators (23).
To determine how sumoylation affects interaction between
DP103 and SF-1, the levels of receptor sumoylation were
driven by the optimal E3-SUMO ligase PIASy. DP103 inter-
acted with SF-1 in the presence of PIASy but not under basal
levels of sumoylation or after addition of SENP1 (Fig. 7A).
Surprisingly, DP103 enhanced PIAS-mediated sumoylation
(two- to threefold) for all PIAS proteins, except PIAS3 (Fig.
7B). No significant increase in sumoylation was observed with
DP103 alone (control). Whether this effect arises from in-
creased ligase activity of PIAS proteins or by protecting sumoy-
lated SF-1 from desumoylation remains to be determined. Fi-
nally, we asked whether DP103 would alter the subnuclear
localization of SF-1. Although our previous results suggested
that the nuclear pattern of SF-1 does not change under basal
levels of sumoylation, a dramatic relocalization of GFP–SF-1
was revealed when DP103 was coexpressed with PIASy and
SUMO1; two representative cells with prominent nuclear bod-
ies are shown (Fig. 7C). Addition of SUMO1, PIASy, or
DP103 alone or a combination of DP103 plus PIAS1, PIASx,
or PIAS3 showed no SF-1 relocalization (Fig. 7C; data not
shown). However, we noted the presence of fine GFP–SF-1
foci in some cells with PIASy alone (Fig. 7C). The ability of
DP103 and PIASy to shuttle SF-1 to discrete nuclear bodies
does not apparently require SF-1 sumoylation, as evidenced by
a speckled pattern after the addition of SENP1 or with the
K119R, K194R, and 2KR GFP–SF-1 mutants (Fig. 7C and
data not shown). Further analysis revealed colocalization of
GFP–SF-1 with PIASy but not with DP103, which localizes to
Cajal bodies or gems (Fig. 7D). These GFP–SF-1 nuclear bod-
ies appear distinct from endogenous splicing speckles, as
shown by the nonoverlapping patterns between GFP–SF-1 and
splicing factor 2 (SF2)ASF. Moreover, these foci do not re-
semble PML nuclear bodies (PML-NBs), given that we failed
to detect obvious PML-NBs in COS-7 cells under our culture
conditions with two markers, Sp100 and PML (Fig. 7D and
data not shown). Collectively, our data suggest that DP103
promotes PIAS-mediated sumoylation and, together with PI-
ASy, relocalizes SF-1 to discrete nuclear foci. Whether these
foci are functionally significant remains to be determined; how-
ever, their formation correlates well with optimal receptor
sumoylation, suggesting a functional complex between SF-1,
PIASy, and DP103.
DISCUSSION
In this study, we report that subfamily V nuclear receptors
are sumoylated at evolutionarily conserved sites. As estab-
lished for other transcription factors, SUMO modification of
SF-1 and LRH-1 significantly attenuates transcriptional activ-
ity. Mutating the acceptor lysines in both SF-1 and LRH-1
resulted in a more active receptor, and at least in the Gal4
context, the relative increase is reminiscent of ligand-depen-
dent receptor activation. Thus, for subfamily V receptors, the
extent of sumoylation represents one mechanism to both reg-
ulate and restrain receptor activity. Our data also suggest that
sumoylation of the so-called repression domain in SF-1/LRH-1
marks the receptor for repression by the DEAD-box protein
DP103. Moreover, this ATPase/RNA helicase was found to
enhance PIAS-dependent receptor sumoylation and to pro-
mote PIASy-dependent shuttling of SF-1 to discrete nuclear
bodies or foci. Subnuclear relocalization of SF-1 correlated
strongly with conditions that promote extensive receptor
sumoylation, suggesting that physical interactions between
SF-1, DP103, and PIASy are linked to transcriptional repres-
sion.
Repression of SF-1 via sumoylation. In contrast to the ubiq-
uitously expressed E1 and E2 sumoylation enzymes, most of
the known E3-SUMO ligases exhibit restricted expression pat-
terns and therefore may direct tissue-specific sumoylation of
protein substrates (48). In considering SF-1 sumoylation, three
E3-SUMO ligases (PIASx, PIASy, and PIAS1) are all highly
expressed in the adult testes (14, 48), where SF-1 regulates
multiple genes. SF-1 is also needed for male sexual differen-
tiation (37, 45), and it is possible that sumoylation of SF-1 is
FIG. 3. Adding SENP1 increases activity of wild-type SF-1 but not
the 2KR sumoylation mutant. (A) A Western blot is shown for COS-7
cells transfected with empty vector (pCI) or wild-type SF-1 (1 g of
each) in the presence or absence of SUMO1 and SENP1 (1 g of
each), with sumoylated SF-1 (arrowhead) and nonsumoylated SF-1
(SF-1) indicated. (B) Effects of increasing amounts of SENP1 (0, 25,
and 50 ng) are shown for transcriptional activity of the Gal4–SF-1 wild
type (pGalWT) and Gal4–SF-1 lysine mutants (pGalK119R,
pGalK194R, and pGal2KR) on the pFR-Luc Gal4 reporter in COS-7
cells. Luciferase activity is expressed in relative luciferase units.
Amounts of transfected plasmids are identical to those used for Fig.
2C. , with; , without; WT, wild type
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sexually dimorphic during development. Thus, silencing of
male-specific genes in the ovary can be partially explained by
lowered levels of SF-1 or by the actions of Dax1 (30, 41) but
may also involve sumoylation. Interestingly, other factors that
function in sexual differentiation, namely Sox9 and WT-1, con-
tain sumoylation sites, and the combinatorial effects of sumoy-
lation may ensure gene silencing in the female. Finally, it is
worth considering the in vivo ratio of nonsumoylated to sumoy-
lated receptors. In this regard, SF-1 haploinsufficiency (2, 28)
may stem from inadequate SF-1 activity due to a reduction of
protein levels coupled with extensive receptor sumoylation.
Currently, our studies are limited to a loss-of-function anal-
ysis. Attempts to provide SUMO1 in cis to SF-1, as shown for
other proteins (18, 50), have failed due to the precise excision
of SUMO1 in COS-7 cells (L. A. Lebedeva and H. A. Ingra-
ham, unpublished data). Whether SF-1 or LRH-1 sumoylation
confers any structural changes to the DBD, hinge, or LBD
remains unclear; however, results from our ChIP analysis sug-
gest that sumoylation does not alter the apparent DNA binding
of a heterologous DBD. Moreover, given that Dax1-mediated
repression of K194R SF-1 mutant is intact, we suggest that no
gross conformational changes occur in the LBD of a sumoyla-
tion-defective receptor. Further structural analyses are needed
and will require an appropriate SUMO–SF-1 chimera or
SUMO stably conjugated to SF-1/LRH-1. Although our find-
ings point to a functional role for Lys194 and Lys289 in SF-1
and LRH-1, respectively, the role of the minor sumoylation
sites at Lys119 or Lys213 (Fig. 1A) is less apparent. Despite the
fact that disumoylated SF-1 is only observed in vivo under
conditions that promote efficient sumoylation, our functional
analyses show that both the minor and major sumoylation sites
act in concert to dampen receptor activity. In this regard, it
remains to be established whether an ordered sumoylation of
SF-1/LRH-1 occurs.
Recent studies report interdependency between sumoyla-
tion and phosphorylation. Mitogen-activated protein kinase-
mediated phosphorylation of Elk-1 greatly reduced sumoyla-
tion at adjacent lysines and led to increased transcriptional
activity (50), and phosphorylation of heat shock factor 1 is a
prerequisite for stress-induced sumoylation (16). Currently, we
find no apparent relationship between phosphorylation of
Ser203 and sumoylation of SF-1. Indeed, the phospho-deficient
FIG. 4. SF-1 sumoylation mutants exhibit wild-type localization, promoter occupancy, and sensitivity to HDAC inhibitors. (A) Nuclear
localization is shown for transfected GFP–SF-1 wild type (WT) and lysine mutants (K119R, K194R, and 2KR) in COS-7 cells; 100 ng of each
plasmid was used and resulted in expression of GFP–SF-1 in 15% of all cells. (B) ChIP assays are shown for the control vector, N-terminal
HA-tagged Gal4–SF-1 (WT), and Gal4 lysine mutants in HeLa cells containing integrated Gal4 response elements fused to luciferase with anti-HA
or control immunoglobulin G (IgG). TSA (C) and NaBT (D) effects on transcriptional activity of the Gal4–SF-1 wild type (pGalWT) and lysine
mutants (pGalK119R, pGalK194R, and pGal2KR) in COS-7 cells. TSA (0 or 333 nM) or NaBT (0, 0.1, 1, or 10 mM) was added to cells at 12 h
posttransfection and incubated for 24 h. Cont., control; HA, anti-HA.
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S203A mutant was efficiently sumoylated, and all SF-1 SUMO
mutants showed equivalent levels of phosphorylated Ser203 in
SF-1 (M. B. Lee, unpublished data). However, it remains pos-
sible that the rate and extent of either phosphorylation or
sumoylation are altered following modification of the Lys194
or Ser203, respectively.
DEAD-box proteins and transcriptional repression. Histor-
ically, DEAD-box (Ddx) RNA helicases are associated with
splicing, in part because they were initially identified as protein
components of the spliceosome (43). However, other functions
for Ddx family members have been noted, and there is mount-
ing evidence that they function to silence transcription factors,
including nuclear receptors, Egr1 to 4, and the Ets-like repres-
sor, METS (12, 21, 36, 49). Additionally, GRTH (Ddx25),
which is expressed in the testes, is reported to attenuate ex-
pression of SF-1 target genes, including steroidogenic enzymes
(10). For DP103 and another DEAD-box protein, DP97, the
repression domain has been mapped to the C-terminal region
and does not require the N-terminal ATPase/helicase domain
characteristic of this gene family (21, 36). Attenuation and
silencing of transcription are multilayered and multidimen-
sional. So how may Ddx proteins and sumoylation lead to
FIG. 5. The DEAD-box protein DP103 mediates SF-1 repression by sumoylation at Lys194 and binds to sumoylated SF-1. (A) Repression of
SF-1 by Dax1 and DP103. Increasing amounts of mDax1 or mDP103 (0, 25, 50, or 150 ng) were cotransfected in COS-7 cells with Gal4–SF-1
(pGalWT) or the pGalK194R (25 ng each) on the Gal4-luciferase reporter (pFR-Luc, 250 ng). (B) Effect of SENP1 on repression by Dax1 and
mDP103. Increasing amounts of Dax1 or DP103 (as in panel A) were cotransfected with control vector (pGal) or the Gal4–SF-1 wild type
(pGal-SF-1), with or without SENP1 (25 ng), on the Gal4-luciferase reporter (as in panel A). (C) GST pull-down assays show binding of the
35S-labeled SF-1 wild type (WT) and lysine mutants (K194R and 2KR) to increasing amounts of GST-hDP103 C-terminal aa 414 to 824
(GST-DPC) (1 and 2 indicate relative amounts used). The 10% input and GST controls are indicated. A schematic of human DP103 shows
the unique C-terminal region and conserved helicase domain motifs (gray rectangles), including the signature DEAD-box motif (black rectangle).
(D) GST pull-down assays show binding of in vitro sumoylated 35S-labeled SF-1 (E1, *SF-1, upper panel) to increasing amounts of GST-hDP103
C-terminal (1, 3, and 9) and to a nonsumoylated SF-1 control made in reactions lacking E1 enzyme (E1, SF-1, lower panel).
1886 LEE ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
transcriptional repression? Recruitment of HDACs upon pro-
tein sumoylation, or by Ddx proteins, offers the most plausible
explanation and is consistent with prior literature. Indeed,
DP103 interacts with the N-terminal repression domain of
METS and promotes HDAC recruitment (21). However, our
data imply that repression through DP103 is TSA and NaBT
insensitive and suggest that repression by Ddx proteins must
involve additional mechanisms other than recruitment of class
I or II HDACs. In considering other mechanisms, it is possible
that DP103 protects SF-1 from desumoylation. This hypothesis
is consistent with the observations that DP103 increased PIAS-
dependent SF-1 sumoylation and that additional SENP1 elim-
inates repression by DP103. The interaction between DP103
and SF-1 remains to be mapped and is likely to involve mul-
tiple interfaces based on our finding that Lys194 and/or sumoy-
lation at Lys119/Lys194 is not the sole determinant of this
interaction. Another possible scenario is that DP103 represses
SF-1 by facilitating PIASy-mediated relocalization of SF-1.
However, we noted that sumoylation is dispensable for move-
ment of SF-1 to nuclear bodies; this observation is reminiscent
FIG. 6. PIASx and PIASy are E3-SUMO ligases for SF-1. (A) Interactions between full-length SF-1 and Gal4AD-PIASx, PIAS1, -PIASy fusion
proteins are shown in yeast expressing SF-1, driving SF-1 response elements fused to LacZ (bar graph) and when grown on X-Gal medium. The bottom
sector (SF-1) shows -galactosidase (-Gal) activity resulting from yeast expressing SF-1 (SF-1) and the empty vector pGADT7. Other sectors show
activity in strains with SF-1 and transformed PIAS fusion proteins, as indicated. Cont., control. (B) A mammalian two-hybrid system showing
transcriptional activity of wild-type pGal4-SF-1 with increasing concentrations of VP16-PIAS fusion proteins (25, 50, or 150 ng). The empty vector control
is shown (pGal). (C) Western blots for COS-7 cells cotransfected with wild-type HA–SF-1, SUMO1, and with individual PIAS proteins or SENP1 are
shown (left panel). The right panel shows a Western blot for HA–SF-1 (WT) and lysine and S203A SF-1 mutants after the addition of PIASx and
SUMO1; 1 g of each plasmid was added. Sumoylated SF-1 (arrowhead) and nonsumoylated SF-1 (SF-1) are indicated. (D) The transcriptional activity
of pGal-SF-1 (25 ng) is shown after increasing amounts of PIASx were cotransfected in COS-7 cells (25, 50, or 150 ng) in the absence or presence of
SUMO1 (25 ng) with the Gal4-luciferase reporter (pFR-Luc, 250 ng). The empty vector control is shown (pGal). (E) Activity of the double sumoylation
mutant of SF-1 (pGal-2KR) is shown after increasing amounts of PIASx, as described for panel C.
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of PIASy-dependent relocalization of both wild-type and
sumoylation-defective Lef1 into nuclear bodies that partially
overlap with PML-NBs (39). Thus, while sumoylation is not
required for subnuclear relocalization of SF-1 (or Lef1), con-
ditions that promote optimal sumoylation do correlate with
altered nuclear distribution of SF-1.
Given that DEAD-box proteins are present in both splicing
and translational complexes (31), repression may be coupled to
transcript processing or translational control. However, studies
to date, including ours, have yet to identify a function for the
RNA helicase (unwindase) and RNA binding motifs in repres-
sion. Indeed, the N-terminal portion of DP103 is dispensable
for interaction and repression of SF-1 and METS (21, 49) and
for relocalization of SF-1 to nuclear bodies (our unpublished
data). Further in vitro and in vivo experiments aimed at delin-
eating the precise role of sumoylation in DEAD-box-mediated
transcriptional repression will be of interest.
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FIG. 7. DP103 interacts with sumoylated SF-1 in vivo and promotes PIASy-mediated SF-1 relocalization into nuclear bodies. (	) Coimmu-
noprecipitation of sumoylated SF-1 from COS-7 cells transfected with wild-type HA–SF-1, SUMO1, and combinations of FLAG-DP103,
T7-PIASy, and SENP1 (1 g of each) with anti-FLAG-M2 agarose beads. Western blots (WB) for HA–SF-1 (3% input lysate, upper panel) and
immunoprecipitated (IP) DP103 (10% IP protein, middle panel) are shown with sumoylated SF-1 indicated (*SF-1). SF-1 (black arrowheads) and
nonspecific bands (NS) are indicated in an anti-HA (HA) Western blot of IP DP103 protein (lower panel). Flag, anti-Flag; DP103, anti-DP103.
(B) Western blots are shown of COS-7 cells cotransfected with wild-type HA–SF-1, SUMO1, and individual PIAS proteins or empty vector (Cont.)
with () or without () DP103 (1 g). Sumoylated SF-1 (arrowhead) and nonsumoylated SF-1 (SF-1) are indicated. (C) Nuclear localization of
GFP–SF-1 transfected into COS-7 cells is shown with different combinations of FLAG-DP103, T7-PIASy, FLAG-PIAS1, and SENP1, as indicated.
All cells were transfected with SUMO1 (100 ng). (D) Subnuclear signals are shown for wild-type GFP–SF-1 (green), and indirect immunofluo-
rescence is shown for T7-PIASy (red) or FLAG-hDP103 (red). Colocalization of GFP–SF-1 and T7-PIASy signals are shown in the merged figure
(upper panels), and the endogenous DP103 signals (lower panels) are indicated (arrowheads). Staining for endogenous SF2/ASF (marker for
splicing speckles) or Sp100 (marker for PML-NBs) is shown (red). Note that no positive staining is observed for endogenous Sp100. In all
conditions, cells were transfected with 100 ng (each) of GFP–SF-1, PIASy, hDP103, and SUMO1.
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